<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984984</url>
  </required_header>
  <id_info>
    <org_study_id>2007-000590-37</org_study_id>
    <secondary_id>ESP/07-09</secondary_id>
    <nct_id>NCT00984984</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses</brief_title>
  <acronym>COPOUSEP</acronym>
  <official_title>Randomised Double-blinded Trial Comparing Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis Relapses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of oral corticosteroids for the treatment of relapses of multiple sclerosis has
      not been proved. French neurologists treat such patients with intravenous corticosteroids.
      The aim of the study is to check if the efficacy of high dose oral methylprednisolone is
      similar to the efficacy intravenous (IV) prednisolone. The main criteria of efficacy is
      symptom recovery within 28 days after inclusion.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>At least 1 point-reduction on Kurtzke functional scale</measure>
    <time_frame>28 days after beginning of corticotherapy</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>methylprednisolone PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>methylprednisolone IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone PO</intervention_name>
    <description>10 capsules Methylprednisolone 100 mg and 50 ml IV NaCl 0,9% (syringe pump 30 mn to 2 h, every day during 3 days</description>
    <arm_group_label>methylprednisolone PO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone IV</intervention_name>
    <description>IV Methylprednisolone 1 g in 50 ml NaCl 0,9% (syringe pump 30 mn to 2 h) and 10 capsules of placebo, every day during 3 days</description>
    <arm_group_label>methylprednisolone IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 to 55

          -  informed written consent

          -  multiple sclerosis (Mc Donald criteria, relapsing-remitting

          -  EDSS before relapse : 0 to 5

          -  relapse : increase of 1 point or more for 1 or more functional systems of Kurtzke,
             with SF score most affected &gt; 1 for all functions except for sensory (&gt; 2); duration
             of symptoms &gt; 24 h

        Exclusion Criteria:

          -  fever

          -  previous relapse, and/or corticosteroid treatment &lt; 1 month before present relapse

          -  first symptoms of the present relapse appeared &gt; 15 days before inclusion

          -  under mitoxantrone of cyclophosphamid or natalizumab treatment

          -  diabetes

          -  infection not under control

          -  liver or kidney failure

          -  psychiatric symptoms not under control

          -  pregnancy

          -  hypersensibility to methylprednisolone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuelle Le Page, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuelle LE PAGE, MD</last_name>
    <phone>33-2-9928-5296</phone>
    <email>emmanuelle.lepage@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Veronique DEBURGHGRAEVE, MD</last_name>
    <phone>33-2-9928-89038</phone>
    <email>veronique.deburghgraeve@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital des Armées</name>
      <address>
        <city>Brest</city>
        <zip>29249</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zagnoli</last_name>
      <email>fabien.zagnoli@wanaddo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rouhart</last_name>
      <email>francois.rouhart@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Vendée</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>de marco</last_name>
      <email>olivier.demarco@chd-vendee.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lannion</name>
      <address>
        <city>Lannion</city>
        <zip>22300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massengo</last_name>
      <email>serge.massengo@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sartori</last_name>
      <email>e.sartori@ch-bretagne-sud.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Laennec</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laplaud</last_name>
      <email>david.laplaud@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Wiertlewski</last_name>
      <email>sandrine.wiertlewski@chu-nantes.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital La pitié Salpétriere</name>
      <address>
        <city>Paris</city>
        <zip>75651 cedex 13</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Papeix</last_name>
      <phone>33 1 42 16 17 51</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Pontivy</name>
      <address>
        <city>Pontivy</city>
        <zip>56300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anani</last_name>
      <email>thierry.anani@ch-pontivy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Cornouaille</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>coustans</last_name>
      <email>m.coustans@ch-cornouaille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de Cornouaille</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coustans</last_name>
      <email>m.coustans@ch-cornouaille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Le Page</last_name>
      <email>emmanuelle.lepage@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Yves Le Foll</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22023</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lallement</last_name>
      <email>francois.lallement@ch-stbrieuc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Saint Malo</name>
      <address>
        <city>Saint Malo</city>
        <zip>35400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>taurin</last_name>
      <email>g.taurin@ch-stmalo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Bretagne Atlantique</name>
      <address>
        <city>Vannes</city>
        <zip>56000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kassiotis</last_name>
      <email>philippe.kassiotis@ch-bretagne-atlantique.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

